Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma
mFOLFIRINOX combined with NK cell therapy demonstrates enhanced antitumor activity against PDAC, potentially improving clinical outcomes. These findings highlight the need for continued research to optimize this combination strategy for clinical utility.
Authors
- Je-Jung Lee (ORCID: https://orcid.org/0000-0003-1939-4364)
- Woo Kyun Bae (ORCID: https://orcid.org/0000-0003-0267-1943)
- Jun‐Eul Hwang (ORCID: https://orcid.org/0000-0002-3768-4149)
- Hye-Seong Park
Institutions
- Chonnam National University Hwasun Hospital (KR)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3390/cancers17172785
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation of Korea